Page 102 - Read Online

Page 12 of 12 Papadodima et al. J Transl Genet Genom 2019;3:7. I https://doi.org/10.20517/jtgg.2018.33

exclusive mutational patterns in tumors. BMC Med Genomics 2011;4:34.
117. Maldonado JL, Fridlyand J, Patel H, Jain AN, Busam K, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst
2003;95:1878-90.
118. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014;9:239-71.
119. Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell 2017;170:17-33.
120. Cox AD, Der CJ. Ras history: the saga continues. Small GTPases 2010;1:2-27.
121. Fedorenko IV, Gibney GT, Smalley KSM. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
Oncogene 2013;32:3009-18.
122. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev
Cancer 2010;10:842-57.
123. Genomic Classification of Cutaneous Melanoma. Cell 2015;161:1681-96.
124. Cirenajwis H, Lauss M, Ekedahl H, Törngren T, Kvist A, et al. NF1-mutated melanoma tumors harbor distinct clinical and biological
characteristics. Mol Oncol 2017;11:438-51.
125. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, et al. Highly recurrent TERT promoter mutations in human melanoma. Science
2013;339:957-9.
126. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, et al. TERT promoter mutations in familial and sporadic melanoma. Science
2013;339:959-61.
127. Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, et al. Genomic and transcriptomic analysis reveals incremental disruption of key
signaling pathways during melanoma evolution. Cancer Cell 2018;34:45-55.e4.
128. Zhao R, Choi BY, Lee MH, Bode AM, Dong Z. Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer.
EBioMedicine 2016;8:30-9.
129. Palmieri G, Colombino M, Casula M, Manca A, Mandalà M, et al. Molecular pathways in melanomagenesis: what we learned from next-
generation sequencing approaches. Curr Oncol Rep 2018;20:86.
130. Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, et al. Comprehensive characterization of cancer driver genes and
mutations. Cell 2018;173:371-85.e18.
131. Ortega-Molina A, Serrano M. PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab 2013;24:184-9.
132. Helgadottir H, Rocha Trocoli Drakensjö I, Girnita A. Personalized medicine in malignant melanoma: towards patient tailored treatment.
Front Oncol 2018;8:202.
133. Mort RL, Jackson IJ, Patton EE. The melanocyte lineage in development and disease. Development 2015;142:620-32.
134. Mehrotra A, Mehta G, Aras S, Trivedi A, de la Serna IL. SWI/SNF chromatin remodeling enzymes in melanocyte differentiation and
melanoma. Crit Rev Eukaryot Gene Expr 2014;24:151-61.